Business

Mass. Movers

Insulet narrows loss in fourth quarter

An earlier version of Insulet’s OmniPod insulin pump.

An earlier version of Insulet’s OmniPod insulin pump.

Advertisement

Bedford’s Insulet Corp. said fourth-quarter 2013 revenue rose 19 percent to $68.5 million, compared to $57.8 million in the same period in 2012. Insulet said the revenue bump was a result of continued strong patient adoption of the OmniPod insulin pump in the United States and international markets. The company said its net loss was $2.5 million, or 4 cents per share, compared to a loss of $10.2 million, or 21 cents, in 2012. The results, however, beats analysts’ estimated loss of 9 cents.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com